Want to see IN:AMRUTANJAN full AI Analyst Report?
Top Page
Amrutanjan Health Care Limited
(AMRUTANJAN)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹507.00
▼(-24.50% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weak recent cash-flow conversion (including negative free cash flow in 2026) and bearish technicals with the stock trading below major moving averages and negative MACD. These are partly offset by a very strong, low-debt balance sheet and stable profitability, while valuation is roughly neutral with a modest dividend yield.
Positive Factors
Very Low Leverage
Extremely low debt limits financial risk, reduces interest burden and gives Amrutanjan flexibility to fund operations or growth internally. The expanding equity base also strengthens resilience against demand volatility in consumer healthcare.
Negative Factors
Weak Cash-Flow Conversion
Weak conversion of accounting profits into cash can constrain internally funded growth and increase working-capital dependence. Negative free cash flow in 2026 is especially important because it may reflect persistent investment or operating cash pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Extremely low debt limits financial risk, reduces interest burden and gives Amrutanjan flexibility to fund operations or growth internally. The expanding equity base also strengthens resilience against demand volatility in consumer healthcare.
Read all positive factors
Amrutanjan Health Care Limited (AMRUTANJAN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹15.02B
Dividend Yield0.95%
Average Volume (3M)37.77K
Price to Earnings (P/E)27.6
Beta (1Y)0.82
Revenue Growth10.68%
EPS Growth-1.04%
CountryIN
Employees634
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)18.67
Shares Outstanding29,230,630
10 Day Avg. Volume1,637
30 Day Avg. Volume37,771
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)3.86
Price to Sales (P/S)2.84
P/FCF Ratio-458.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amrutanjan Health Care Limited Business Overview & Revenue Model
Company Description
Established in Chennai, India, in 1893, Amrutanjan Health Care Limited, formerly known as Amrutanjan Limited until its renaming in 2007, is a prominent manufacturer, supplier, and vendor of a broad array of wellness products. The company primarily...
How the Company Makes Money
Amrutanjan Health Care Limited makes money primarily by selling branded consumer healthcare products (mainly OTC pain-relief and wellness items) to distributors/wholesalers, retailers, and other channel partners, which then sell to end consumers. ...
Amrutanjan Health Care Limited Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
90
Very Positive
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.11B | 5.03B | 4.51B | 4.21B | 3.80B | 4.05B |
| Gross Profit | 2.27B | 1.88B | 2.46B | 1.46B | 1.98B | 2.25B |
| EBITDA | 782.80M | 756.85M | 758.79M | 681.60M | 590.79M | 946.99M |
| Net Income | 539.72M | 579.18M | 508.35M | 449.73M | 398.35M | 671.89M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.09B | 4.21B | 3.67B | 3.62B | 3.50B |
| Cash, Cash Equivalents and Short-Term Investments | 1.79B | 363.99M | 1.95B | 2.07B | 1.93B | 2.01B |
| Total Debt | 0.00 | 17.77M | 20.78M | 17.28M | 9.09M | 8.80M |
| Total Liabilities | -3.70B | 1.39B | 947.73M | 783.82M | 713.21M | 847.44M |
| Stockholders Equity | 3.70B | 3.70B | 3.27B | 2.88B | 2.91B | 2.65B |
Cash Flow | ||||||
| Free Cash Flow | -78.22M | -31.16M | 153.46M | 211.93M | 102.91M | 287.32M |
| Operating Cash Flow | 109.07M | 518.88M | 508.99M | 279.11M | 192.18M | 521.96M |
| Investing Cash Flow | -82.16M | -371.49M | -309.66M | 191.65M | -24.75M | -362.12M |
| Financing Cash Flow | -76.94M | -136.22M | -134.90M | -482.66M | -140.26M | -167.02M |
Amrutanjan Health Care Limited Technical Analysis
Positive
671.50
Price Trends
506.30
Positive
525.99
Negative
557.56
Negative
Market Momentum
1.01
Negative
58.05
Neutral
63.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AMRUTANJAN, the sentiment is Positive. The current price of 671.5 is above the 20-day moving average (MA) of 500.36, above the 50-day MA of 506.30, and above the 200-day MA of 557.56, indicating a neutral trend. The MACD of 1.01 indicates Negative momentum. The RSI at 58.05 is Neutral, neither overbought nor oversold. The STOCH value of 63.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AMRUTANJAN.
Amrutanjan Health Care Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹72.75B | 53.95 | ― | 0.22% | 20.59% | 27.16% | |
74 Outperform | ₹23.85B | 20.77 | ― | 0.56% | 20.87% | 116.29% | |
69 Neutral | ₹89.04B | 24.85 | ― | 3.94% | 13.04% | 4.60% | |
59 Neutral | ₹1.04T | 51.22 | ― | 0.04% | 13.75% | 6.23% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹15.02B | 27.64 | ― | 0.95% | 10.68% | -1.04% | |
47 Neutral | ₹23.23B | 862.24 | ― | 0.08% | 12.08% | ― |
* General Sector Average
IN:AMRUTANJAN
Amrutanjan Health Care Limited
513.80
-193.98
-27.41%
IN:BLISSGVS
Bliss Gvs Pharma Limited
684.20
530.83
346.12%
IN:INDOCO
Indoco Remedies Limited
251.70
-31.85
-11.23%
IN:MANKIND
Mankind Pharma Ltd.
2,527.00
75.10
3.06%
IN:PGHL
Procter & Gamble Health Ltd.
5,363.95
-606.69
-10.16%
IN:VENUSREM
Venus Remedies Limited
1,784.40
1,316.32
281.21%
Amrutanjan Health Care Limited Corporate Events
Amrutanjan Files SEBI Demat Compliance Certificate for Q1 FY2026-27
Jul 8, 2026
Amrutanjan Health Care Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The filing underscores the company’s ongoing obl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.